CAR therapy has achieved profound efficacy and multiple approvals by the US Food & Drug Administration, particularly in the form of therapies targeting CD19 and B-cell maturation antigen (BCMA) expressed in hematologic malignancies(6). This evidence concerns the gene TNFRSF17 and hematologic disorder.